Olink Explore HT

About Olink Proteomics

Olink Proteomics was founded to overcome the limitations of traditional proteomics, providing a platform for accurate, high-throughput protein analysis. Its core Proximity Extension Assay (PEA) technology achieved widespread adoption in major academic and pharmaceutical research, culminating in its 2024 acquisition by Thermo Fisher Scientific. The company's strategy focuses on enabling the entire biomarker pipeline, from large-scale discovery to the development of validated clinical signatures, now amplified by Thermo Fisher's global commercial and R&D infrastructure.

Therapeutic Areas